Neuren Pharmaceuticals (ASX:NEU)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health Check: UBS turns ultra-bullish on Aussie healthcare leaders
Big Freeze puts MND in focus – and the Aussie tech helping sufferers take back control
Biocurious: Nyrada looks to change the treatment landscape for brain and heart disorders
Scott Power: ASX health stocks rise as Healthscope landlord agrees to rent deferral deal
As AI rewires microbiology, Clever Culture’s lab tech is catching Big Pharma’s eye
Health Check: Optiscan perfects ‘dial a pathologist’ platform; 4D Medical probes further FDA approval
Aussie researchers and ASX biotechs driving paediatric drug breakthroughs
Health Check: To chagrin of short sellers, Polynovo shares soar on type 1 diabetes breakthrough
Health Check: Neuren says more patients are staying the course as US Daybue sales lift
Lunch Wrap: ASX back to the grind after US Fed rate hold; Locksley doubles on US rare earths hunt
Closing Bell: ASX sticks the landing with 1.34pc lift
Lunch Wrap: ASX surges on Washington relief, Neuren rockets and GGE leads small caps
Biocurious: While other biotechs scratch around for cash, Clinuvel is accused of having too much
